ENDPOINTS

#AACR25: Revolution’s KRAS drug shows potential in early cut of lung cancer data

An experimental KRAS G12D drug from Revolution Medicines made waves last year as a potential treatment for pancreatic cancer. On Sunday, new results from an early data readout showed it works on lung cancer as ...

Apr 28, 2025 - 08:07
 0
#AACR25: Revolution’s KRAS drug shows potential in early cut of lung cancer data
An experimental KRAS G12D drug from Revolution Medicines made waves last year as a potential treatment for pancreatic cancer. On Sunday, new results from an early data readout showed it works on lung cancer as ...
Read More

Tags:

Previous Article

#AACR25: Keytruda around head and neck cancer surgery cuts chance of disease com...

Next Article

Regeneration, super strength, stolen powers: Meet sea creatures inspiring research

Related Posts

AbbVie eyes $10B US expansion amid sector-specific tariff threat

AbbVie eyes $10B US expansion amid sector-specific tari...

Apr 25, 2025  0

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche takes steps to protect itself from tariffs, while...

Apr 24, 2025  0

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

FDA chief Makary talks expediting drug approvals, RIFs ...

Apr 25, 2025  0